Consider buying Bitcoin (BTC) or MicroStrategy (MSTR) near the end of the U.S. trading day to potentially capitalize on a recurring daily price dip. For investors interested in the telehealth sector, LifeMD (LFMD) is presented as a more attractive and cheaper alternative to Hims & Hers Health (HIMS) at current valuations. Investors are advised to be cautious about adding to HIMS near its all-time high, as it may be due for a pullback. Similarly, the investment opportunity in Figma was at its IPO price, and it is no longer considered an attractive buy at its current elevated price. This leaves LFMD as the primary "buy" recommendation from these insights.

Bitcoin (BTC) & MicroStrategy (MSTR)

• The speaker notes that MicroStrategy (MSTR) is holding a conference call featuring well-known Bitcoin advocates Preston Pish and Lynn Alden, which is viewed as a very positive and "wise" move.
• A recurring price pattern in Bitcoin is highlighted, where the price tends to drop towards the end of the U.S. trading day (around 3 p.m. EST) and then immediately bounces back after the market closes.
• The speaker describes this short-term price action as "manipulation" and "very frustrating," attributing it to hedge fund trading strategies.

Takeaways

• Potential Trading Strategy: The speaker suggests that investors looking to add to Bitcoin or MSTR positions could "wait until the end of the day" to potentially buy at a lower price, taking advantage of the observed daily dip.
• Sentiment: The sentiment on MSTR is implicitly bullish due to the positive commentary on CEO Michael Saylor's strategic use of respected industry experts.
• Risk Factor: Investors should be aware of significant short-term volatility and what the speaker perceives as price manipulation in Bitcoin, which can affect related stocks like MSTR.

Hims & Hers Health (HIMS)

• HIMS has experienced a "stunning rally" and is trading near its all-time high.
• The speaker believes the stock might be getting "a little out of itself" and is "climbing a little fast."
• He discloses that HIMS is his third-largest position and that he originally invested around $6 per share.
• Due to the rapid price increase and his already large position, he states, "I would not be adding HIMS at these levels."

Takeaways

• Sentiment: Short-term cautious/bearish. While the speaker is clearly a long-term bull on the company, he is advising caution at current price levels due to the rapid run-up.
• Actionable Insight: Investors who have seen significant gains in HIMS might consider trimming their position or holding off on adding more until a potential pullback. The stock is considered expensive at its current price by the speaker.

LifeMD (LFMD)

• The speaker analyzes LifeMD (LFMD) as a "pair" to HIMS, constantly evaluating which of the two is a better value.
• Currently, the speaker argues that LFMD "looks more interesting" and is the "cheaper stock" of the two.
• He states, "I would be more interested in adding to LifeMD than I would be interested in adding to HIMS" at this time.

Takeaways

• Sentiment: Bullish. LFMD is presented as the more attractive investment opportunity compared to HIMS at current valuations.
• Actionable Insight: This is a classic pair trade idea. The speaker suggests that LFMD may have more upside potential from its current price compared to the high-flying HIMS. Investors looking for exposure to the telehealth sector might find LFMD to be a better entry point.

Figma (IPO)

• The speaker participated in the Figma IPO via Robinhood and had a "sour experience," receiving an allocation of only one share.
• He believes the IPO was "mispriced" and "should have priced much higher," noting he found it "very undervalued at $33" (the IPO price) when compared to a company like Adobe.
• With the stock now trading around $112, his view has changed: "I don't like it as much. It's more expensive now."
• He is frustrated by a rule that prevents him from selling the single share for 30 days without being flagged, trapping him in the position.

Takeaways

• Sentiment: The sentiment has shifted from bullish at the $33 IPO price to neutral/bearish at the current market price of $112.
• Valuation Insight: The primary investment opportunity in Figma was at its IPO price. At over 3x that price, the speaker no longer sees it as an attractive investment and will not be buying shares if it "stays sky high."
• IPO Risk: The speaker highlights a key risk of participating in highly anticipated IPOs on retail platforms: you may tie up a significant amount of cash for a very small (or even single-share) allocation, making the opportunity cost high for a minimal potential gain.